Trials / Active Not Recruiting
Active Not RecruitingNCT04856085
Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection
A Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Regimens Containing VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 244 (actual)
- Sponsor
- Vir Biotechnology, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 2 study in which participants with chronic hepatitis B virus (HBV) infection will receive VIR-2218, VIR-3434 and/or PEG-IFNα and be assessed for safety, tolerability, and efficacy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VIR-2218 | VIR-2218 given by subcutaneous injection |
| DRUG | VIR-3434 | VIR-3434 given by subcutaneous injection |
| DRUG | PEG-IFNα | PEG-IFNα given by subcutaneous injection |
Timeline
- Start date
- 2021-07-11
- Primary completion
- 2026-03-01
- Completion
- 2026-03-01
- First posted
- 2021-04-22
- Last updated
- 2025-10-21
Locations
37 sites across 12 countries: United States, Canada, Germany, Hong Kong, Malaysia, Moldova, New Zealand, Romania, South Korea, Taiwan, Ukraine, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04856085. Inclusion in this directory is not an endorsement.